سعر تروسبامكسين Trospamexin‏ 20مجم 20 قرص 2026

Trospium chloride 20 mg film-coated tablets, pack of 20 (2 strips), by EVA Pharma (Egypt); quaternary ammonium antimuscarinic for overactive bladder.

• Most common: dry mouth (20.1% vs 5.8% placebo) and constipation; less common: trouble emptying the bladder, blurred vision and heat prostration. Post-marketing: palpitations, supraventricular tachycardia, Stevens-Johnson syndrome, anaphylaxis, angioedema, dizziness, confusion, hallucinations, delirium, rhabdomyolysis, rash.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, and patients at risk for these conditions.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to trospium chloride (angioedema, rash, anaphylaxis have been reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Risk of urinary retention in patients with clinically significant bladder outflow obstruction.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Angioedema of the face, lips, tongue and/or larynx has been reported; discontinue promptly and treat if involvement of the tongue, hypopharynx or larynx occurs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Use with caution in gastrointestinal obstructive disorders, ulcerative colitis, intestinal atony and myasthenia gravis (decreased gastrointestinal motility).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Drugs eliminated by active tubular secretion (e.g. procainamide, pancuronium, morphine, vancomycin, tenofovir)Potential for competition for renal tubular secretion, increasing serum concentrations of trospium and/or the other drug; monitor closely.DailyMed (U.S. National Library of Medicine)
• Other antimuscarinic agentsIncreased frequency/severity of dry mouth, constipation and other anticholinergic effects; may also alter absorption of some concomitant drugs via effects on GI motility.DailyMed (U.S. National Library of Medicine)
• MetforminCo-administration reduced trospium exposure (AUC by about 29%, Cmax by about 34%); clinical significance unknown.DailyMed (U.S. National Library of Medicine)

• Pregnancy Category C (historical US letter category on this label): no adequate and well-controlled studies in pregnant women; use during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Based on animal data, trospium chloride is predicted to have a low probability of increased risk of adverse developmental outcomes above background risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Trospium was excreted (less than 1%) into the milk of lactating rats; excretion into human milk is unknown; use during lactation only if the potential benefit justifies the potential risk to the newborn.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Trospium chloride: Muscarinic receptor antagonist; antagonises acetylcholine at bladder muscarinic receptors, reducing detrusor smooth muscle tone.